Cite
HARVARD Citation
Sternberg, C. et al. (2023). FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. Journal of clinical oncology. 41 (3), pp. 629-639. [Online].